Peter J. Richardson

4-8 Maple Street, W1T 5HD
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.

Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.

Journal: Molecular cancer therapeutics
Published: September 06, 2024

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.

Journal: Translational neurodegeneration
Published: July 13, 2023

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19.

Baricitinib as the treatment of choice for hospitalised individuals with COVID-19.

Journal: EClinicalMedicine
Published: May 16, 2022

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19.

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19.

Journal: Vaccines
Published: April 14, 2022

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.

Journal: JAMA
Published: October 04, 2021

Epigenome-wide association study of sarcopenia: findings from the Hertfordshire Sarcopenia Study (HSS).

Epigenome-wide association study of sarcopenia: findings from the Hertfordshire Sarcopenia Study (HSS).

Journal: Journal of cachexia, sarcopenia and muscle
Published: May 21, 2021

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19.

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19.

Journal: Frontiers in pharmacology
Published: May 14, 2021

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

Journal: Science advances
Published: August 24, 2020

Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.

Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.

Journal: Cancer discovery
Published: August 15, 2020

The Emergence of Baricitinib: A Story of Tortoises Versus Hares.

The Emergence of Baricitinib: A Story of Tortoises Versus Hares.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 25, 2020

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.

Journal: EMBO molecular medicine
Published: May 16, 2020

CNS penetration of potential anti-COVID-19 drugs.

CNS penetration of potential anti-COVID-19 drugs.

Journal: Journal of neurology
Published: April 23, 2020
Showing 1-12 of 24

Last Updated: 09/26/2026